Cargando…

Cost of epilepsy-related health care encounters in the United States

BACKGROUND: The cost of epilepsy is usually reported as total expenditure over a certain period. However, with the increased availability of acute treatments for use in the community setting, intermittent, single-seizure treatment is now possible in addition to the chronic epilepsy drug treatment pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Borghs, Simon, Beaty, Silky, Parekh, Witesh, Kalilani, Linda, Boudiaf, Nada, Loewendorf, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390911/
https://www.ncbi.nlm.nih.gov/pubmed/33103619
http://dx.doi.org/10.18553/jmcp.2020.20111
_version_ 1785082581535948800
author Borghs, Simon
Beaty, Silky
Parekh, Witesh
Kalilani, Linda
Boudiaf, Nada
Loewendorf, Andrea
author_facet Borghs, Simon
Beaty, Silky
Parekh, Witesh
Kalilani, Linda
Boudiaf, Nada
Loewendorf, Andrea
author_sort Borghs, Simon
collection PubMed
description BACKGROUND: The cost of epilepsy is usually reported as total expenditure over a certain period. However, with the increased availability of acute treatments for use in the community setting, intermittent, single-seizure treatment is now possible in addition to the chronic epilepsy drug treatment paradigm. Data on the cost of discrete health care encounters are needed to substantiate the cost-benefit of these new treatments. OBJECTIVE: To estimate the health plan-paid costs of discrete epilepsy-related health care encounters in patients with epilepsy. METHODS: This retrospective cohort study utilized IBM MarketScan Commercial Claims, Medicare Supplemental and Coordination of Benefits (Medicare patients with supplemental insurance), and Multi-State Medicaid research databases. The primary analysis determined health plan-paid cost (adjudicated claims) of discrete epilepsy-related health care encounters, defined as having a primary diagnosis code of epilepsy or convulsion, from 2013 to 2018, in patients with epilepsy aged ≥ 12 years. Costs were adjusted to 2018 prices. Epilepsy cases were defined using ICD-CM codes. We excluded patients on capitated insurance plans as their cost per health care encounter is unknown. RESULTS: In total, 353,530 commercially insured, 378,051 Medicaid, and 69,176 Medicare plus supplemental insurance patients with epilepsy were included. More than 160,000 epilepsy-related emergency transportations, 225,000 emergency department (ED) visits, 49,000 hospitalizations, 700 urgent care visits, and ~2.5 million office visits were analyzed. 37.4% of epilepsy-related hospitalizations included care in the intensive care unit (ICU). In commercially insured patients, epilepsy-related health care encounters had median health plan-paid costs of $22,305 (Q1-Q3 = $14,336-$36,096, hospitalization); $3,375 ($565-$9,095, ICU visit); $1,913 ($417-$4,163, ED visit); $687 ($415-$1,083, emergency transportation); $95 ($23-$232, office visit); and $57 ($0-$171, urgent care visit). The median length of stay for epilepsy-related hospitalizations in working age, commercially insured patients was 4 (Q1-Q3 = 2-5) days. CONCLUSIONS: This is the first study to report health plan-paid cost per epilepsy-related health care encounter. These data can serve as a basis for more granular cost-benefit analyses of not only chronic but also acute treatments of epilepsy.
format Online
Article
Text
id pubmed-10390911
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Academy of Managed Care Pharmacy
record_format MEDLINE/PubMed
spelling pubmed-103909112023-08-02 Cost of epilepsy-related health care encounters in the United States Borghs, Simon Beaty, Silky Parekh, Witesh Kalilani, Linda Boudiaf, Nada Loewendorf, Andrea J Manag Care Spec Pharm Research Brief BACKGROUND: The cost of epilepsy is usually reported as total expenditure over a certain period. However, with the increased availability of acute treatments for use in the community setting, intermittent, single-seizure treatment is now possible in addition to the chronic epilepsy drug treatment paradigm. Data on the cost of discrete health care encounters are needed to substantiate the cost-benefit of these new treatments. OBJECTIVE: To estimate the health plan-paid costs of discrete epilepsy-related health care encounters in patients with epilepsy. METHODS: This retrospective cohort study utilized IBM MarketScan Commercial Claims, Medicare Supplemental and Coordination of Benefits (Medicare patients with supplemental insurance), and Multi-State Medicaid research databases. The primary analysis determined health plan-paid cost (adjudicated claims) of discrete epilepsy-related health care encounters, defined as having a primary diagnosis code of epilepsy or convulsion, from 2013 to 2018, in patients with epilepsy aged ≥ 12 years. Costs were adjusted to 2018 prices. Epilepsy cases were defined using ICD-CM codes. We excluded patients on capitated insurance plans as their cost per health care encounter is unknown. RESULTS: In total, 353,530 commercially insured, 378,051 Medicaid, and 69,176 Medicare plus supplemental insurance patients with epilepsy were included. More than 160,000 epilepsy-related emergency transportations, 225,000 emergency department (ED) visits, 49,000 hospitalizations, 700 urgent care visits, and ~2.5 million office visits were analyzed. 37.4% of epilepsy-related hospitalizations included care in the intensive care unit (ICU). In commercially insured patients, epilepsy-related health care encounters had median health plan-paid costs of $22,305 (Q1-Q3 = $14,336-$36,096, hospitalization); $3,375 ($565-$9,095, ICU visit); $1,913 ($417-$4,163, ED visit); $687 ($415-$1,083, emergency transportation); $95 ($23-$232, office visit); and $57 ($0-$171, urgent care visit). The median length of stay for epilepsy-related hospitalizations in working age, commercially insured patients was 4 (Q1-Q3 = 2-5) days. CONCLUSIONS: This is the first study to report health plan-paid cost per epilepsy-related health care encounter. These data can serve as a basis for more granular cost-benefit analyses of not only chronic but also acute treatments of epilepsy. Academy of Managed Care Pharmacy 2020-12 /pmc/articles/PMC10390911/ /pubmed/33103619 http://dx.doi.org/10.18553/jmcp.2020.20111 Text en Copyright © 2020, Academy of Managed Care Pharmacy. All rights reserved. https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Research Brief
Borghs, Simon
Beaty, Silky
Parekh, Witesh
Kalilani, Linda
Boudiaf, Nada
Loewendorf, Andrea
Cost of epilepsy-related health care encounters in the United States
title Cost of epilepsy-related health care encounters in the United States
title_full Cost of epilepsy-related health care encounters in the United States
title_fullStr Cost of epilepsy-related health care encounters in the United States
title_full_unstemmed Cost of epilepsy-related health care encounters in the United States
title_short Cost of epilepsy-related health care encounters in the United States
title_sort cost of epilepsy-related health care encounters in the united states
topic Research Brief
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390911/
https://www.ncbi.nlm.nih.gov/pubmed/33103619
http://dx.doi.org/10.18553/jmcp.2020.20111
work_keys_str_mv AT borghssimon costofepilepsyrelatedhealthcareencountersintheunitedstates
AT beatysilky costofepilepsyrelatedhealthcareencountersintheunitedstates
AT parekhwitesh costofepilepsyrelatedhealthcareencountersintheunitedstates
AT kalilanilinda costofepilepsyrelatedhealthcareencountersintheunitedstates
AT boudiafnada costofepilepsyrelatedhealthcareencountersintheunitedstates
AT loewendorfandrea costofepilepsyrelatedhealthcareencountersintheunitedstates